The profile is currenly unclaimed by the seller. All information is provided by CB Insights.


Series A | Alive

Total Raised


Last Raised

$28.39M | 7 yrs ago

About Kesios Therapeutics

Kesios Therapeutics is developing novel therapeutics for the treatment of multiple myeloma and other cancers. KES-0001, the company's lead drug candidate, is about to enter clinical studies as a potential treatment for multiple myeloma.

Kesios Therapeutics Headquarter Location

Bessemer Building Levels 1 & 2

London, England, SW7 2AZ,

United Kingdom

+44 (0) 203 818 9280

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Kesios Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Kesios Therapeutics is included in 2 Expert Collections, including Biopharma Tech.


Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.



3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

Latest Kesios Therapeutics News

UK-based Kesios Therapeutics closes a £19M Series A financing from Imperial Innovations, SV Life Sciences and Abingworth

Dec 4, 2015

04/12/2015 · United Kingdom · Pharma & Biotech · Abingworth , Imperial Innovations , SV Life Sciences Kesios Therapeutics Ltd (“Kesios”), an earlystage company developing novel therapeutics for the treatment of multiple myeloma and other cancers, has announced the successful closing of a £19 million (approx. $28.5 million) Series A financing. The syndicate compromises a consortium of leading venture investors, including Imperial Innovations Group plc (AIM: IVO), and international investment groups, SV Life Sciences and Abingworth. “Kesios has made swift progress in building a world-class management team to advance its innovative science and drug development. Being able to attract coinvestors such as SV Life Sciences and Abingworth is testament to the potential of Kesios’ approach,” noted Maina Bhaman, Director of Healthcare Ventures, Imperial Innovations. As part of the Series A Investment Kate Bingham, SV Life Sciences, and Kurt von Emster, Abingworth, have joined the Kesios Board. Kate Bingham, Managing Partner at SV Life Sciences said: “We are thrilled to be backing such a strong oncology management team, led by Dr Paoletti, with a great record in translating novel scientific ideas into clinically meaningful new drugs for patients.” “Kesios’ novel targeted oncology approach and innovative global clinical path makes this an exciting investment,” said Kurt von Emster, Managing Partner of Abingworth. Kesios is developing drug candidates that exploit a novel target within the nuclear factor kappa B (NF-κB) pathway. The target appears to be critical in promoting cancer cell survival in certain white blood cells of patients with multiple myeloma and other malignancies. Concurrent with the financing, Kesios has expanded its leadership team appointing Paolo Paoletti, MD, as Chief Executive Officer. He joined the company as Executive Chairman earlier in 2015. Jane Robertson, MD, joined as Chief Medical Officer after leading clinical development activities at AstraZeneca for a number of oncology products, including most recently the development and registration in the EU and US of Lynparza®. Peter Charlton was appointed Chief Scientific Officer having previously worked at Vertex as VP, Biology. Dayle Hogg has also joined Kesios as Chief Operating Officer following his role as an investment manager at Imperial Innovations. “With this substantial Series A financing, a team of experienced and highly motivated scientists, supported by a strong investment syndicate, has been put in place to deliver a new treatment option for patients with multiple myeloma,” said Paolo Paoletti, CEO. “The science developed at Imperial College London has led to the identification of a new target pathway to exploit in multiple myeloma and a clinical candidate that appears to restore apoptosis in myeloma cancer cells. We are now well placed to explore if this novel mechanism of action may have an impact on patients with multiple myeloma,” Dr Paoletti added.  

  • Where is Kesios Therapeutics's headquarters?

    Kesios Therapeutics's headquarters is located at Bessemer Building Levels 1 & 2, London.

  • What is Kesios Therapeutics's latest funding round?

    Kesios Therapeutics's latest funding round is Series A.

  • How much did Kesios Therapeutics raise?

    Kesios Therapeutics raised a total of $31.39M.

  • Who are the investors of Kesios Therapeutics?

    Investors of Kesios Therapeutics include Touchstone Innovations, SV Health Investors and Abingworth.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.